Previous 10 |
Small molecule lead drug candidate blocks a critical target for tumors and crosses the blood brain barrier; begins first brain cancer patient dosing in clinical trial at MD Anderson Cancer Center HOUSTON, Sept. 13, 2018 (GLOBE NEWSWIRE) -- In the ongoing challenge to combat the almos...
Moleculin Biotech ( MBRX ) Q2 results : Revenues: $0; R&D Expense: $4.2M; SG&A: $1.2M (+50.0%); Net Loss: ($5.1M) (-50.0%); Loss Per Share: ($0.20) (-5.3%). More news on: Moleculin Biotech, Inc., Healthcare stocks news, Earnings news and commentary, , Read more ...
HOUSTON, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas Syst...
News, Short Squeeze, Breakout and More Instantly...
Moleculin Biotech Inc. Company Name:
MBRX Stock Symbol:
NASDAQ Market:
Moleculin Biotech Inc. Website:
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.7% to $109.21 on volume of 508,402,989 shares Redhill Biopharma Ltd. (RDHL) rose 97.9% to $0.76 on volume of 355,380,053 shares PROSHARES TRUST (SQQQ) rose 7.3% to $9.22 on volume of 284,777,109 shares ...
Moleculin Announces Plans for MIRACLE Phase 3 Pivotal Trial PR Newswire Based on an encouraging discussion in the End of Phase 1B /2 Meeting with FDA the Company plans to: Proceed with a pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) designed for po...
Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML PR Newswire HOUSTON , July 10, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfoli...